Teva Pharma In Talks With Trump Administration On Medicaid Drug Pricing Initiative

Teva’s U.S. affiliate said it shares an agreement with the Trump Administration to lower the cost of select medicines for Medicaid patients. The company also indicated support for continued investment, but no specific pricing reductions, timeframe, or financial impact were provided in the excerpt. Overall, the update is policy- and reputation-focused with limited clarity on near-term earnings effects.